Visfatin is an adipocytokine and a potential biomarker encoded by the nicotinamide phosphoribosyltransferase gene. It belongs to the nicotinic acid phosphoribosyltransferase family and involved in various metabolic processes and aging. The aim of this study was to evaluate the role of visfatin biomarker in oral diseases like periodontitis. A total of 60 patients (20–50 years) were included in this study, and they were divided into three groups. Group I consisted of 20 subjects with healthy periodontium, group II consisted of 20 subjects with generalized moderate gingivitis, and group III consisted of 20 subjects with generalized periodontitis. The clinical periodontal parameters, including plaque index, gingival index, probing pocket depth, and clinical attachment levels, were recorded, and saliva samples were collected. Salivary visfatin concentrations were assessed using standard enzyme-linked immunosorbent assay. The results of the study showed that the visfatin concentrations were higher in patients with gingivitis and periodontitis compared with those of healthy individuals. Visfatin was found highest in group III (38.22 ± 3.38 ng/mL) followed by group II (26.66 ± 2.24 ng/mL) and the group I (25.60 ± 2.19 ng/mL). Thus, salivary visfatin is a potential inflammatory biomarker and acts as a mediator in the pathogenesis of periodontal disease and, might serve as a diagnostic and therapeutic biomarker in oral diseases like periodontitis.
Background: Vitamin D deficiency is a major public health problem in all age groups. Through its immunomodulatory, anti-inflammatory and antioxidant effects it is shown to have a protective effect in COVID affected children. The objective of the study was to evaluate vitamin D deficiency as a risk factor for developing COVID-19 infection in children and to study the relationship between vitamin D deficiency and the clinical findings in COVID-19 positive children.Methods: A retrospective study of all COVID positive children aged 1 month to 15 years admitted to COVID Paediatric ward of Rajarajeshwari Medical hospital from July 2020-November 2020. All COVID positive children confirmed with RTPCR of age group 1 month to 15 years will be included in the study the age at admission, clinical and laboratory data, and 25‐hydroxycholecalciferol (25‐OHD) levels will be recorded. Patients diagnosed with COVID 19 are divided into 2 groups those with deficient and insufficient vitamin D levels were determined as group 1 and patients with normal vitamin D levels as Group 2. Those with vitamin D Levels below 20ng/ml were determined as group 1 and those with >20 ng/ml as group 2. The various clinical outcomes and laboratory parameters were compared between the two groups.Results: Patients with COVID 19 had significantly lower vitamin D levels 22.39±6.27 (p≤0.0001). Patients in group A that is vitamin D deficient and insufficient group had higher levels of ferritin (p≤0.0001).No significant difference was found between other clinical and laboratory parameters between group 1 and group 2.Conclusions: This is one of the first to evaluate vitamin D levels and its relationship with clinical findings in paediatric patients with covid-19. Although vitamin D does not play a role in the pathogenesis of COVID-19 we do believe its putative role in preventing and treating the disease The results suggest that vitamin D levels may be associated with the occurrence and management of the COVID-19 disease by modulating the immunological mechanism to the virus in paediatric population.
The ability to correctly diagnose and institute effective periodontal therapy is essential to control periodontal diseases. Rapid advances in diagnostic research are moving towards methods whereby periodontal disease risk can be identified and quantified by measuring biomarkers. This study investigated the effect of Non-Surgical Periodontal Treatment (NSPT) on clinical indices and salivary levels of visfatin in subjects with increasing severity of the periodontal disease. This interventional clinical trial was performed on 60 systemically healthy male and female subjects (20 to 50 years) who were categorised into Group-1, Twenty subjects with healthy periodontium, Group-2, Twenty subjects with generalized moderate gingivitis, and Group-3 (20 subjects with moderate to severe periodontitis (Stage III according to the new classification of periodontal diseases). The visfatin levels were measured in unstimulated saliva by using standard EnzymeLinked Immunosorbent Assay (ELISA) technique at baseline and six weeks after NSPT. The salivary visfatin levels were highest in Group-3 (38.22±3.38 ng/ml) followed by Group - 2 (26.66±2.24 ng/ml) and Group-1 (25.60±2.19 ng/ml) at baseline. After NSPT statistically significant reduction in salivary visfatin levels (p<0.001) in Groups -2 and 3 were seen. Visfatin levels at baseline were almost equivocal in normal weight and overweight subjects, irrespective of body mass index and showed a statistically significant reduction in salivary visfatin levels in both groups six weeks after NSPT (p<0.001). The present study suggests that salivary visfatin is a strong contributor in the pathology of periodontal disease and can be used as its diagnostic/therapeutic biomarker.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.